Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/903,822external-prioritypatent/US20110092415A1/en
Priority claimed from US13/100,827external-prioritypatent/US8937150B2/en
Application filed by Abbvie IncfiledCriticalAbbvie Inc
Publication of ECSP14012622ApublicationCriticalpatent/ECSP14012622A/en
Compuestos eficaces para inhibir la replicación del virus de la hepatitis C ("HCV"); procesos de elaboración de tales compuestos, composiciones que los comprenden y métodos de uso de los mismos para tratar una infección por HCV.Effective compounds for inhibiting the replication of the hepatitis C virus ("HCV"); manufacturing processes of such compounds, compositions comprising them and methods of using them to treat an HCV infection.
Compounds derived from macrocyclic prolines, inhibitors of hepatitis C virus serine proteases (vhc); pharmaceutical composition that includes them; and its use to treat a viral infection such as hepatitis C virus (vhc) infection.
Compounds derived from thiophene-2-carboxylic acid, flaviviridae virus inhibitors; pharmaceutical composition that includes them; and its use for the treatment of a viral infection by flaviviridae.
Compounds derived from biphenyl-pyrrolidinyl-imidazole; pharmaceutical composition comprising them; its use in the treatment of an hcv viral infection.
Compounds derived from imidazo [1,2-f] [1,2,4] triazinyl nucleosides; pharmaceutical composition that includes them; and its use for the treatment of a flaviviridae virus infection, particularly hepatitis c virus infections.
Benzimidazole-imidazole derivative compounds, hepatitis c virus (hcv) inhibitors; pharmaceutical composition comprising them; pharmaceutical combination; use in the prevention or treatment of hcv infection.
Compounds derived from substituted piperazin-pyridin-biphenyl-imidazole-pyrrolidines, hepatitis C virus replication inhibitors (hcv); pharmaceutical composition that includes them; process to prepare a compound; method to treat an hcv virus infection; and use to treat an hcv virus infection.
Compounds derived from nucleosides, hepatitis c virus inhibitors; preparation procedure; pharmaceutical composition that includes them; and pharmaceutical combination.
Compounds derived from substituted 4'-azido-3'-deoxy-3'-fluoro nucleosides; pharmaceutical composition comprising said compounds and the use thereof to treat a hepatitis c virus (hcv) infection.